A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children
Status:
Completed
Trial end date:
2001-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and maximum tolerated dose (the highest
dose that can be given safely) of recombinant Interleukin-2 (rIL-2) in HIV-infected children.
This study also evaluates the effect of rIL-2 on the immune system of these patients.
IL-2 is a substance naturally produced by the body's white blood cells that plays an
important role in helping the body fight infection. HIV-infected patients do not produce
enough IL-2, and it is hoped that the use of rIL-2 may improve immune system function in
these patients. First, it is necessary to determine the safety and effectiveness of this drug
in HIV-infected children.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)